Mesothelial Neoplasms
46 drugs in active Mesothelial Neoplasms trials · Updated 18 Nov 2026
Furthest along
2 in Phase 3
22 in Phase 2
Drugs
46
In active trials, any stage
Trials
45 active
1 sub-disease included
Drugs46
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 3 | 1 May 2028Phase 3 trial completes | |||
| Next date | 1 May 2028 · Phase 3 trial completes | ||||
| Also tested for | Mesothelioma, Pleural Mesothelioma and 10 more | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
AstraZeneca · Public AZN |
Phase 3 | 16 Nov 2028Phase 3 trial completes | ||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | 16 Nov 2028 · Phase 3 trial completes | ||||
| Also tested for | Unresectable Pleural Mesothelioma | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Malignant Pleural Mesotheliomas | ||||
| Open drug page | |||||
PD-1 antibody |
Merck & Co. · Public MRK |
Phase 2 | 4 May 2027Phase 2 trial completes | ||
| Next date | 4 May 2027 · Phase 2 trial completes | ||||
| Also tested for | Endometrial Carcinoma, Endometrial Cancer and 57 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Jun 2027Phase 1/2 trial completes | |||
| Next date | Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Locally Advanced Solid Tumor | ||||
| Open drug page | |||||
— |
Phase 1/2 | 31 Aug 2027Phase 1/2 trial completes | |||
| Next date | 31 Aug 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Malignant Mesothelioma, Metastatic Malignant Solid Tumor and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 31 Dec 2027Phase 1/2 trial completes | |||
| Next date | 31 Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Cancer, Advanced Solid Tumor and 16 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Dec 2027Phase 1/2 trial completes | |||
| Next date | Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Head and Neck Carcinoma, Adenoid Cystic Carcinoma and 23 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 31 Jan 2028Phase 1/2 trial completes | |||
| Next date | 31 Jan 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Pancreatic Ductal Adenocarcinoma, Gastric Cancer and 6 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Jan 2028Phase 1/2 trial completes | |||
| Next date | Jan 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumor Malignancies, Malignant Mesothelioma (MM) | ||||
| Open drug page | |||||
No drugs match “”.
Included1
| Sub-disease | Drugs | Active trialsTrials |
|---|---|---|
| Mesothelioma 1 sub-disease | 46 | 45 |
About
- Summary
- 46 drugs are in active Mesothelial Neoplasms trials: 2 in Phase 3, 44 earlier. The next Phase 3 result expected is VT3989’s, 1 May 2028. Updated 18 Nov 2026.
- Registry term
- Neoplasms, Mesothelial
- Counts
- Active trials the registry tags with the term or a term under it, at any stage. A search also reads trial titles and drug names, so its counts differ.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026